Research Context - Read Before Proceeding
All claims in this article reference preclinical (animal) or in vitro research unless explicitly stated otherwise. No compound discussed here is approved for human therapeutic use in South Africa unless specifically noted. Citations are provided for every material claim - see the References section below. This content is for scientific and educational purposes only. It does not constitute medical advice and must not be interpreted as a therapeutic recommendation. 18+ · Research use only.
The Epistemics of Knowing What You Have
Research produces conclusions. Conclusions depend on data. Data depends on knowing what you actually administered. And knowing what you actually administered depends entirely on having independent verification that your compound is what you think it is.
This is not a bureaucratic requirement. It is the foundation of any valid research process.
A supplier can tell you their compound is 99% pure. They can print that on the vial. They can include a glossy certificate with their company logo on it. None of that constitutes verification. Verification requires an independent party - an accredited analytical laboratory with no financial stake in the result - to test the actual compound and issue a document stating what they found.
That document is the Certificate of Analysis. Understanding what it contains, how to read it, and where suppliers cut corners is essential knowledge for any researcher working with peptide compounds.
---
## What a Valid CoA Actually Contains
A legitimate third-party Certificate of Analysis for a research peptide should contain seven pieces of information:
Compound identity confirmation. Mass spectrometry (MS) confirms that the molecule's measured molecular weight matches the theoretical molecular weight of the target compound. This confirms you have the right compound. HPLC purity data without identity confirmation tells you something is 98% pure - but not what that something is.
Purity percentage by HPLC. High-Performance Liquid Chromatography separates the components of the sample and reports each as a percentage of the total signal. Your target compound's peak area divided by the total peak area equals the purity percentage. For pharmaceutical-grade peptides, the standard is 98%+.
Impurity profile. What is in the other 1-5%? Truncated sequences, deletion peptides, oxidised variants, residual solvents? The nature of the impurities matters as much as the total impurity level. A CoA that states only the purity percentage without characterising what the impurities are is providing incomplete information.
Analytical method specification. What HPLC method was used? What was the column, the mobile phase, the detection wavelength? Without this, you cannot assess whether the methodology was appropriate for the compound being tested, and the result cannot be independently reproduced.
Batch/lot number. This is the link between the document and your specific vial. The lot number on the CoA must match the lot number on your vial. A CoA from a previous batch does not verify the batch in your hands. This is a routine supplier shortcut - a CoA is valid, but it is for a different batch.
Date of analysis. When was the testing conducted? A CoA issued two years ago may reflect the compound's specification at manufacture, not its current state.
Issuing laboratory. The name, accreditation status, and contact information of the third-party laboratory. If this information is absent or if the issuing entity is the supplier itself, it is not an independent CoA.
---
## Third-Party vs In-House: Why This Distinction Is Non-Negotiable
Every supplier has an incentive to report their compounds as pure. That incentive does not disappear because they are the ones doing the testing. In-house testing is the supplier assessing their own product and reporting the result. There is no independent check on the methodology, no accountability for a failing result, and no separation between commercial interest and analytical conclusion.
Third-party testing removes that conflict of interest. An accredited analytical laboratory has no stake in whether your peptide is 95% pure or 99% pure. Their business is accurate testing. Their reputation, accreditation status, and legal liability depend on reporting what they actually found, not what the supplier would prefer them to report.
When you design research based on a compound's documented properties, you need to know that documentation came from someone with no motive to misrepresent. That requires third-party independence. There is no substitute.
---
## Pharmaceutical-Grade: What the Term Actually Means
"Pharmaceutical-grade" is used loosely in the supplement and research industries. In the context of peptide compounds, it should mean specific, verifiable things:
Purity 98%+. Not 95%, which is a common "research grade" standard. The additional 3% matters because the impurity profile at 95% is larger and less well-characterised than at 98%.
Residual solvent limits. Peptide synthesis uses organic solvents - TFA (trifluoroacetic acid), acetonitrile, DMF among others. Pharmaceutical-grade synthesis controls residual solvent content to defined limits. TFA in particular is worth testing for specifically: it forms a stable counter-ion with the basic groups of peptides and can persist through purification if not specifically removed.
Endotoxin testing. Bacterial endotoxins from the synthesis resin and cleavage process can trigger severe biological responses. Pharmaceutical-grade specifies endotoxin limits tested against LAL (Limulus Amebocyte Lysate) assays. This is not optional for compounds intended for any biological system.
Enantiomeric purity. Amino acids exist as L and D stereoisomers. Biological peptides are built from L-amino acids. Solid-phase peptide synthesis can introduce D-amino acid contamination through racemisation. Pharmaceutical-grade synthesis confirms correct stereoisomer composition.
---
## Red Flags in Supplier Documentation
| Red Flag | What It Actually Means |
| Supplier cannot produce CoA on request before purchase | Verification either does not exist or cannot be matched to specific batches |
These are not minor administrative issues. Each represents a gap in your ability to know what you are actually working with. A research protocol built on unverified compounds produces uninterpretable data.
---
## What a CoA Does Not Guarantee
A CoA verifies the compound at a specific point in time from a specific batch. It does not guarantee that the compound in your vial is still at that specification.
Cold-chain integrity after the CoA was issued is not captured in the document. If the compound was temperature-compromised during shipping, storage, or handling, the actual purity at your point of use may be substantially below what the CoA states. The CoA documents what was manufactured. Your storage protocol determines what you actually research.
The CoA also does not constitute a safety or efficacy claim for any use. It confirms chemical identity and purity. That is all it does, and it is enough - as long as you understand its scope and maintain the cold-chain integrity that ensures your compound remains what the CoA says it is.
18+ only. Research use only. Not for human consumption.